In contrast to previous findings, a nested case–control study did not find evidence of an increased risk of cardiac events associated with the use of strontium ranelate in women with postmenopausal osteoporosis. Using the UK Clinical Practice Research Datalink (CPRD) and linked datasets, the researchers evaluated annual incidence rates for first definite myocardial infarction (1,352 cases), myocardial infarction with hospitalization (1,465 cases) and cardiovascular death (3,619 cases) in women treated for postmenopausal osteoporosis with strontium ranelate. Neither current nor past use of strontium ranelate was associated with an increased risk of a cardiac event.
References
Cooper, C. et al. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD. Osteoporos. Int. 10.1007/s00198-013-2582-4
Rights and permissions
About this article
Cite this article
Cardiac safety of strontium ranelate. Nat Rev Endocrinol 10, 128 (2014). https://doi.org/10.1038/nrendo.2013.267
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.267